Hosted on MSN1mon
Viking Therapeutics targets Phase 3 trials for VK2735 in Q2 2025 amid strong clinical progressAnnabel Samimy, Stifel: Asked about plans for an auto-injector for subcutaneous VK2735. Lian confirmed the intention to use an auto-injector in Phase 3 trials, potentially requiring a bridging ...
Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...
Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...
Nucala is given as a subcutaneous injection ... the medication at home using the prefilled syringe or prefilled auto-injector. Nucala injections are given under the skin of the thigh, abdomen ...
Chief executive Chris Viehbacher said on Biogen's results call that a plan to extend the use of the subcutaneous injector into the induction phase of treatment could be a "game changer." ...
Bruising, redness, itching, pain, or swelling at the injection site may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly. Remember that this medication has ...
Immunovant’s IMVT-1402 is highlighted as the most convenient FcRn inhibitor in late-stage development, featuring an easy-to-use subcutaneous auto-injector. The drug’s potential for deeper IgG ...
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results